Neoadjuvant immunotherapy in resectable hepatocellular carcinoma: A meta-analysis of the current evidence

doi:10.5306/wjco.v16.i10.110511

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 16, Issue 10

This Article

(73)

(75)

(0)

(984)

(1)

Peer-Review Report of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Supplementary Materials of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Journal Information of This Article

Publication Name

World Journal of Clinical Oncology

ISSN

2218-4333

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Meta-Analysis

World J Clin Oncol. Oct 24, 2025; 16(10): 110511
Published online Oct 24, 2025. doi: 10.5306/wjco.v16.i10.110511

Full Size Figure Download Figure

Figure 1 PRISMA flow diagram. Flow diagram summarizing the study selection process. A total of 395 studies were initially identified, of which 12 met the inclusion criteria and were included in the final meta-analysis.

Citation: Cicerone O, Oliviero B, Mantovani S, Maiocchi L, Ravetta V, Berton F, Corallo S, Vanoli A, Maestri M. Neoadjuvant immunotherapy in resectable hepatocellular carcinoma: A meta-analysis of the current evidence. World J Clin Oncol 2025; 16(10): 110511
URL: https://www.wjgnet.com/2218-4333/full/v16/i10/110511.htm
DOI: https://dx.doi.org/10.5306/wjco.v16.i10.110511

Cicerone O, Oliviero B, Mantovani S, Maiocchi L, Ravetta V, Berton F, Corallo S, Vanoli A, Maestri M. Neoadjuvant immunotherapy in resectable hepatocellular carcinoma: A meta-analysis of the current evidence. World J Clin Oncol 2025; 16(10): 110511 [PMID: 41178932 DOI: 10.5306/wjco.v16.i10.110511]

All content on this site: Copyright © 1993-2026 Baishideng Publishing Group Inc, its licensors, and contributors. All rights are reserved, including those for text and data mining, AI training, and similar technologies. For all open access content, the relevant licensing terms apply.